Biomarkers for radiation treatment
AssigneeVarian Medical Systems, Inc.
InventorRenate Parry
Life of this patent
Estimating the term…
Abstract
The methods described herein allow for the classification of patients into groups for receiving optimized radiation treatment based on patient specific biomarker signature. The biomarker signature includes markers that have been shown to correlate with TGF-β expression and to be associated with tumor aggressiveness, radioresistance and poor prognosis. The markers play a key role in the epithelial-mesenchymal transition. The methods described herein provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining TGF-β inhibitors with ionizing radiation to treat cancer patients.
Claims8
A method for treating a tumor in a subject, the method comprising:
- i) contacting a tumor sample from the subject with antibodies that bind to biomarkers CD44 and CD68;
- ii) contacting a normal tissue sample with antibodies that bind to the biomarkers CD44 and CD68;
- iii) detecting increased expression of CD44 and CD68 in the tumor sample as compared to the normal tissue sample, and
- iv) administering an effective dose of ionizing radiation to the tumor and a TGF-beta inhibitor to the subject, thereby treating the tumor, wherein the TGF-beta inhibitor is an antibody or a small molecule.
Dependencies are inferred from the claim text.